Inogen Releases Innovative Inogen One G5™ Portable Oxygen Concentrator

At only 4.7 pounds and 6 flow settings, the Inogen One G5 is the most balanced portable oxygen concentrator Inogen has ever created to meet the needs of oxygen therapy patients and home medical equipment providers – for use at home, away, and for travel. The Inogen One G5 represents a step forward in innovation, as it is the highest oxygen output per pound of weight of any portable oxygen concentrator currently available in the homecare market in the United States. With 1,260 ml of oxygen production capacity and Inogen’s standard Intelligent Delivery Technology®, the Inogen One G5 was designed to meet the clinical needs of 95% of patients that express an interest in Inogen’s products for long-term oxygen therapy. Other patient-preferred features include a long battery life of up to 13 hours with the optional double battery, access to Inogen Connect, a large LCD screen, and very quiet operation.

It is Inogen’s mission to push the boundaries of conventional design and to develop innovative and patient-preferred oxygen technology to help patients reclaim their freedom and independence.

“The Inogen One G5 exemplifies Inogen’s spirit of innovation and dedication to designing products specifically for the end consumer, the oxygen therapy user, while also taking into account the needs of the homecare provider,” said Scott Wilkinson, Inogen’s CEO. “We are extremely proud of the level of innovation that we are delivering to patients, and we look forward to hearing about the lives changed because of the Inogen One G5.”

The Inogen One G5 has been released for sale to oxygen therapy patients in the Company’s domestic direct-to-consumer sales channel and is expected to be made available to additional sales channels, including domestic and international business-to-business channels (pending receipt of any required foreign regulatory approvals), through a controlled rollout process over the coming months.

Additional specifications for the Inogen One G5 can be found on page 2:

Inogen has used, and intends to continue to use, its Investor Relations website, http://investor.inogen.com/, as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. For more information, visit http://investor.inogen.com/.

Cautionary Note Concerning Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements concerning Inogen’s expectations for market acceptance of its Inogen One G5, the ability of the Inogen One G5 to meet the clinical needs of patients, Inogen’s belief that the Inogen One G5 can change and improve the lives of patients, and the expected timing and distribution channels for the rollout of the Inogen One G5. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to, risks relating to market acceptance of Inogen’s products; competition; its sales, marketing and distribution capabilities; its planned sales, marketing, and research and development activities; interruptions or delays in the supply of components or materials for, or manufacturing of, its products; seasonal variations in customer operations; unanticipated increases in costs or expenses; risks associated with international operations, including risks associated with obtaining regulatory approval in foreign jurisdictions; and intellectual property risks if Inogen is unable to secure and maintain patent or other intellectual property protection for the intellectual property used in its products. Information on these and additional risks, uncertainties, and other information affecting Inogen’s business and operating results are contained in Inogen’s Annual Report on Form 10-K for the year ended December 31, 2018 and in Inogen’s subsequent reports filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Inogen disclaims any obligation to update these forward-looking statements except as may be required by law.

About Inogen

Inogen is innovation in oxygen therapy. We are a medical technology company that develops, manufactures and markets innovative oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

For more information, please visit www.inogen.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190403005276/en/